According to a new study a history of using marijuana is not associated with a decrease in survival rates among liver transplant patients, despite some marijuana users being denied such transplants.
The study was conducted by researchers at the University of Ottawa and the University of British Columbia, and is published in the Canadian Liver Journal and the US National Library of Medicine.
With the “aim to investigate liver transplantation candidacy and outcomes among cannabis users”, researchers conducted a meta-analysis of eight peer-reviewed studies involving over 5,000 patients.
“The proportion of patients listed for liver transplantation was significantly less among cannabis users than among non-users”, states the study. Researchers note that “While only 14% of Canadian centres had a policy in place and preferred candidates to abstain or decrease cannabis use before transplantation, a third of Canadian centres rejected cannabis users.”
Observational studies “failed to demonstrate significant differences in patient survival between pre-transplantation cannabis users and non-users.” However, “self-reported mental health ratings were worse in post-transplantation cannabis users than in non-users and former users.”
“Cannabis use has not been associated with poor patient outcomes in terms of 1-, 3-, and 5-year patient survivals”, states the study. “Therefore, liver transplant candidates who use cannabis should not be denied access to transplantation.”
You can find the full text of the study by clicking here. The full abstract can be found below.
Background: Recreational cannabis was legalized in Canada in 2018. A controversial contraindication for liver transplantation is cannabis. There is currently no consensus regarding cannabis use in liver transplant candidates. We aim to investigate liver transplantation candidacy and outcomes among cannabis users.
Methods: English peer-reviewed studies on PubMed and Google Scholar were searched on September 9, 2022, using keywords including “cannabis,” “liver transplantation,” and their synonyms. Titles and abstracts were screened, followed by full texts. Reference lists were reviewed. Studies that investigated liver transplantation candidacy and outcomes among cannabis users were included.
Results: The proportion of patients listed for liver transplantation was significantly less among cannabis users than among non-users. Time to listing was longer for cannabis users than non-users. The incidence of delisting was similar. There is an inconsistency between transplant centres regarding transplantation candidacy for cannabis users. While only 14% of Canadian centres had a policy in place and preferred candidates to abstain or decrease cannabis use before transplantation, a third of Canadian centres rejected cannabis users. Observational studies failed to demonstrate significant differences in patient survival between pre-transplantation cannabis users and non-users. However, self-reported mental health ratings were worse in post-transplantation cannabis users than in non-users and former users.
Conclusions: Current observational data do not support a link between cannabis use and poor patient survival post-transplantation. However, high-quality prospective studies are needed to better elucidate the impact of cannabis use on liver transplantation outcomes. Liver transplant candidacy should be evaluated through a multidisciplinary and comprehensive approach considering all relevant psychosocial factors.
